Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
PCSK9 Inhibitor (siRNA — Small Interfering RNA)

Inclisiran

Brand names: Leqvio

Inclisiran is a subcutaneously administered small interfering RNA therapy that lowers LDL cholesterol in primary hypercholesterolaemia and mixed dyslipidaemia, given infrequently after initial loading.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a small interfering RNA that silences hepatic PCSK9 messenger RNA, reducing PCSK9 production so more LDL receptors remain available to clear LDL cholesterol.

Prescribing in practice

  • It is used as an adjunct to diet and maximally tolerated statin therapy, or with other lipid-lowering drugs when statins are unsuitable, with NICE restricting use by LDL threshold and cardiovascular risk.
  • Injection-site reactions are the most common adverse effect.
  • Administration is by a healthcare professional, after loading doses, then maintained at infrequent intervals.

Monitoring

A lipid profile confirms response; no specific routine laboratory drug monitoring is otherwise mandated.

Counselling the patient

  • This treatment is given as an injection only a few times a year after the first doses.
  • Continue your statin and healthy lifestyle measures unless advised otherwise.
  • Mild injection-site reactions such as redness may occur and usually settle.

Evidence & guidelines

The ORION trial programme demonstrated sustained LDL reduction with twice-yearly maintenance dosing, supporting NICE-approved use in eligible patients.

Reference: ORION-10 trial (Ray et al. NEJM 2020); ORION-9 trial; NICE TA733; MHRA SPC Leqvio 2020; NHS England commissioning guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways